Overview

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Status:
Completed

Trial end date:
2014-04-30

Target enrollment:

Participant gender:

Summary

This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild to moderate Alzheimer's disease.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal